Estimated Control (100%) Closed Transaction verified GlaucomaOphthalmic PharmaceuticalsOphthalmologyPharmaPharmaceuticals

Aerie Pharmaceuticals, Inc. acquired by Alcon Research, Ltd.

Alcon Research, Ltd. acquired Aerie Pharmaceuticals, Inc., a US ophthalmic pharmaceuticals brand, on Aug 22, 2022.

Transaction summary

Target
Aerie Pharmaceuticals, Inc.
Acquirer
Alcon Research, Ltd.
Seller
Aerie Pharmaceuticals, Inc. shareholders
Announced
2022-08-22
Geography
United States
Tags
GlaucomaOphthalmic PharmaceuticalsOphthalmologyPharmaPharmaceuticals
Type
Acquisition
Deal type
Control
Stake acquired
100%
First added
2026-08-08
Latest update
2026-08-08

Value and multiples

Price / value

USD 750M

Enterprise Value | USD

Basis: Public source

EV / revenue

4.4x

Period not stated

Basis: FundComb estimate

EV / EBITDA

-

EBITDA basis not stated

Basis: FundComb estimate

Basis

  • USD 750m enterprise value is treated as publicly disclosed or derived directly from public source data.
  • EV / revenue: 4.4x.
  • Revenue and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.

Source summary

No public source summary has been published for this transaction yet.